Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension – CATALYST
Condition(s):Connective Tissue Disease-Associated Pulmonary Arterial HypertensionLast Updated:February 6, 2024Terminated
Hide Studies Not Open or Pending
Condition(s):Connective Tissue Disease-Associated Pulmonary Arterial HypertensionLast Updated:February 6, 2024Terminated
Condition(s):Connective Tissue Disease-associated Interstitial Lung Disease; Interstitial Lung Disease; Connective Tissue DiseasesLast Updated:June 11, 2020Unknown status
Condition(s):Connective Tissue Diseases; ThrombocytopeniaLast Updated:September 21, 2023Not yet recruiting
Condition(s):Systemic Sclerosis Associated Interstitial Lung Disease; Rheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD); Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)Last Updated:January 3, 2024Not yet recruiting
Condition(s):Lung Diseases, InterstitialLast Updated:February 2, 2024Recruiting
Condition(s):Lung Diseases, InterstitialLast Updated:January 29, 2024Not yet recruiting
Condition(s):Interstitial Lung Disease; Scleroderma; Idiopathic Inflammatory Myositis; Mixed Connective Tissue DiseaseLast Updated:October 7, 2021Completed
Condition(s):Interstitial Lung DiseaseLast Updated:November 24, 2023Recruiting
Condition(s):Connective Tissue Diseases; Blood Coagulation Disorders; Leg Ulcers; Rheumatoid Arthritis; Systemic Lupus Erythematosus; Systemic Scleroderma; Mixed Connective Tissue DiseaseLast Updated:August 30, 2017Completed
Condition(s):Pulmonary Arterial HypertensionLast Updated:April 8, 2019Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.